Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STK3 | Q13188 | 8/20 | 0.81 |
| ▸ | CDC7 | O00311 | 2/20 | 0.81 |
| ▸ | MARK3 | P27448 | 2/20 | 0.81 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.81 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.81 |
| ▸ | PLK4 | O00444 | 1/20 | 0.81 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.81 |
| ▸ | AURKA | O14965 | 1/20 | 0.81 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.81 |
| ▸ | JAK2 | O60674 | 1/20 | 0.81 |
| ▸ | PAK4 | O96013 | 1/20 | 0.81 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.81 |
| ▸ | EGFR | P00533 | 1/20 | 0.81 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.81 |
| ▸ | PRKCG | P05129 | 1/20 | 0.81 |
| ▸ | INSR | P06213 | 1/20 | 0.81 |
| ▸ | LCK | P06239 | 1/20 | 0.81 |
| ▸ | FYN | P06241 | 1/20 | 0.81 |
| ▸ | CDK1 | P06493 | 1/20 | 0.81 |
| ▸ | LYN | P07948 | 1/20 | 0.81 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15401270 | 0.87 | LRRK2 (1.00) | STK3CDC7MARK3ROCK2ROCK1 | |
| SCHEMBL15401984 | 0.86 | LRRK2 (1.00) | STK3CDC7MARK3ROCK2ROCK1 | |
| SCHEMBL28000043 | 0.85 | STK3 (0.74) | STK3CDC7MARK3ROCK2ROCK1 | |
| SCHEMBL3535044 | 0.85 | LRRK2 (1.00) | STK3CDC7MARK3ROCK2ROCK1 | |
| SCHEMBL15400907 | 0.84 | LRRK2 (1.00) | STK3CDC7MARK3ROCK2ROCK1 | |
| SCHEMBL15401331 | 0.80 | LRRK2 (1.00) | STK3CDC7MARK3JAK2JAK3 | |
| SCHEMBL9966954 | 0.79 | AKT1 (0.85) | GSK3BKIT | |
| SCHEMBL20640921 | 0.79 | AKT1 (0.85) | STK3CDC7MARK3ROCK2ROCK1 | |
| SCHEMBL31301601 | 0.78 | LRRK2 (0.77) | STK3CDC7MARK3ROCK2ROCK1 | |
| SCHEMBL4432115 | 0.78 | LMNA (0.72) | AURKAAURKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3719018-A1 | PURINE AND DEAZAPURINE DERIVATIVES AS PHARMACEUTICAL COMPOUNDS | Astex Therapeutics Ltd (GB) | 2020-10-07 | — | — | EP | disclosed |
| EP-3421471-A1 | PURINE AND DEAZAPURINE DERIVATIVES AS PHARMACEUTICAL COMPOUNDS | Astex Therapeutics Limited (GB) | 2019-01-02 | — | — | EP | disclosed |
| US-9006430-B2 | Ortho-condensed pyridine and pyrimidine derivatives (e.g., purines) as protein | ASTEX THERAPEUTICS LIMITED (GB) | 2015-04-14 | — | — | US | disclosed |
| US-20140303177-A1 | ORTHO-CONDENSED PYRIDINE AND PYRIMIDINE DERIVATIVES (E.G., PURINES) AS PROTEIN KINASES INHIBITORS | ASTEX THERAPEUTICS LIMITED (GB) | 2014-10-09 | — | — | US | disclosed |
| US-8809336-B2 | Ortho-condensed pyridine and pyrimidine derivatives (e.g., purines) as protein kinases inhibitors | ASTEX THERAPEUTICS LIMITED (GB) | 2014-08-19 | — | — | US | disclosed |
| US-8796293-B2 | Purine and deazapurine derivatives as pharmaceutical compounds | ASTEX THERAPEUTICS LIMITED (GB) | 2014-08-05 | — | — | US | disclosed |
| US-20140107137-A1 | Ortho-Condensed Pyridine and Pyrimidine Derivatives (e.g., Purines) as Protein Kinases Inhibitors | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2014-04-17 | — | — | US | disclosed |
| US-8546407-B2 | Ortho-condensed pyridine and pyrimidine derivatives (e.g., purines) as protein kinases inhibitors | ASTEX THERAPEUTICS LIMITED (GB) | 2013-10-01 | — | — | US | disclosed |
| CN-101489559-B | Purine and deazapurine derivatives as pharmaceutical compounds | ASTEX THERAPEUTICS LTD | 2012-08-15 | — | — | CN | disclosed |
| EP-1812004-B1 | ORTHO- CONDENSED PYRIDINE AND PYRIMIDINE DERIVATIVES (E. G. PURINES) AS PROTEIN KINASES INHIBITORS | ASTEX THERAPEUTICS LTD (GB) | 2011-06-22 | — | — | EP | disclosed |
| EP-2272517-A1 | Ortho-condensed pyridine and pyrimidine derivatives ( e.g. purines ) as protein kinases inhibitors | Astex Therapeutics Limited (GB) | 2011-01-12 | — | — | EP | disclosed |
| US-20100022564-A1 | PURINE AND DEAZAPURINE DERIVATIVES AS PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2010-01-28 | — | — | US | disclosed |
| US-20090247538-A1 | Ortho-Condensed Pyridine and Pyrimidine Derivatives (e.g., Purines) as Protein Kinases Inhibitors | ASTEX THERAPEUTICS LIMITED (UK) | 2009-10-01 | — | — | US | disclosed |
| CN-101489559-A | Purine and deazapurine derivatives as pharmaceutical compounds | ASTEX THERAPEUTICS LTD (GB) | 2009-07-22 | — | — | CN | disclosed |
| CN-101484173-A | Pharmaceutical combinations of pk inhibitors and other active agents | ASTEX THERAPEUTICS LTD (GB) | 2009-07-15 | — | — | CN | disclosed |
| EP-2043655-A2 | PURINE AND DEAZAPURINE DERIVATIVES AS PHARMACEUTICAL COMPOUNDS | Astex Therapeutics Limited (GB) | 2009-04-08 | — | — | EP | disclosed |
| US-20090082370-A1 | Pharmaceutical Combinations of PK Inhibitors and Other Active Agents | ASTEX THERAPEUTICS LIMITED (GB) | 2009-03-26 | — | — | US | disclosed |
| EP-2037931-A2 | PHARMACEUTICAL COMBINATIONS OF PK INHIBITORS AND OTHER ACTIVE AGENTS | Astex Therapeutics Limited (GB) | 2009-03-25 | — | — | EP | disclosed |
| WO-2007125321-A2 | PURINE AND DEAZAPURINE DERIVATIVES AS PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2007-11-08 | — | — | WO | disclosed |
| WO-2007125310-A2 | PHARMACEUTICAL COMBINATIONS OF PK INHIBITORS AND OTHER ACTIVE AGENTS | ASTEX THERAPEUTICS LIMITED (GB) | 2007-11-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140107137-A1 | Ortho-Condensed Pyridine and Pyrimidine Derivatives (e.g., Purines) as Protein Kinases Inhibitors | CDK1, CDK2, CDK3 | STK3 360/4885CDC7 273/4885MARK3 197/4885 |
| US-20090247538-A1 | Ortho-Condensed Pyridine and Pyrimidine Derivatives (e.g., Purines) as Protein Kinases Inhibitors | CDK2, CDK1, OXSR1 | STK3 393/4885CDC7 258/4885MARK3 281/4885 |
| US-20140303177-A1 | ORTHO-CONDENSED PYRIDINE AND PYRIMIDINE DERIVATIVES (E.G., PURINES) AS PROTEIN KINASES INHIBITORS | CDK2, CDK1, CDK3 | STK3 359/4885CDC7 271/4885MARK3 196/4885 |
| US-20090082370-A1 | Pharmaceutical Combinations of PK Inhibitors and Other Active Agents | PKN2, PKN1, PKN3 | STK3 79/4885CDC7 1142/4885MARK3 103/4885 |
| US-20100022564-A1 | PURINE AND DEAZAPURINE DERIVATIVES AS PHARMACEUTICAL COMPOUNDS | TPMT, CNKSR1, PRKD3 | STK3 736/4885CDC7 1096/4885MARK3 336/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.